D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $21.00 price target on the stock. D. Boral Capital’s target price would indicate a potential upside of 364.60% from the company’s […]
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They presently have a $21.00 price target on the stock. D. Boral Capital’s target price would indicate a potential upside of 364.60% from the company’s […]
